MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Avanos Medical Financial Ratios 2011-2026 | AVNS
Annual Financial Ratios Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-8.6 | -1.8 | -11.8 | 26.9 | 264.7 | -75.6 | -29.3 | 37.3 | 29.0 | 44.4 | -2.7 | 76.5 | - | - | - |
P/S |
0.9 | 1.0 | 1.1 | 2.0 | 2.2 | 3.1 | 1.9 | 3.3 | 3.8 | 1.1 | 0.7 | 1.2 | - | - | - |
EPS |
-1.6 | -8.5 | -1.3 | 1.1 | 0.1 | -0.6 | -1.0 | 1.2 | 1.7 | 0.8 | -9.2 | 0.6 | 3.3 | 3.3 | - |
EV (Enterprise Value) |
834 M | 939 M | 1.1 B | 1.73 B | 1.88 B | 2.5 B | 1.67 B | 2.29 B | 3.06 B | 2.62 B | 1.97 B | 2.96 B | 361 M | 431 M | - |
EBITDA per Share |
-0.49 | -7.62 | 1.08 | 1.77 | 1.01 | -0.12 | -0.395 | 0.72 | 0.35 | 3.27 | 3.47 | 3.86 | - | - | - |
EV/EBITDA |
39.1 | -710.5 | -73.7 | 59.0 | 162.3 | 14.6 | 9.9 | 14.3 | - | - | - | ||||
PEG |
0.02 | 0.01 | 0.05 | -0.14 | -1.15 | 1.77 | 0.16 | -1.34 | 0.3 | 0.41 | 0.0 | -0.98 | - | - | - |
P/B |
0.8 | 0.9 | 0.6 | 1.1 | 1.3 | 1.7 | 1.1 | 1.7 | 1.9 | 1.6 | 1.1 | 1.4 | - | - | - |
P/CF |
8.4 | 7.2 | 22.6 | 14.9 | 19.1 | -877.2 | -10.7 | -11.0 | 22.8 | 11.1 | 42.5 | 29.9 | - | - | - |
ROE % |
-9.37 | -47.33 | -5.00 | 3.91 | 0.50 | -2.30 | -3.63 | 4.43 | 6.52 | 3.61 | -40.40 | 1.82 | - | - | - |
ROA % |
-6.79 | -33.97 | -3.65 | 2.83 | 0.39 | -1.73 | -2.55 | 3.14 | 3.61 | 1.92 | -21.31 | 1.07 | - | - | - |
ROCE % |
-7.92 | -47.82 | 0.34 | 2.75 | 0.82 | -3.84 | -3.51 | 0.03 | -2.39 | 5.00 | 5.72 | 4.34 | - | - | - |
Current Ratio |
3.6 | 3.5 | 3.7 | 3.6 | 4.8 | 4.0 | 2.5 | 2.7 | 3.0 | 1.8 | 2.1 | 1.9 | - | - | - |
DSO |
61.6 | 73.1 | 84.2 | 79.8 | 58.8 | 69.5 | 85.7 | 84.2 | 121.1 | 43.6 | 52.1 | 51.1 | - | - | - |
DIO |
150.7 | 179.8 | 219.7 | 220.1 | 158.1 | 167.1 | 180.3 | 169.5 | 121.0 | 96.2 | 106.1 | 92.0 | - | - | - |
DPO |
57.7 | 65.9 | 77.2 | 78.3 | 59.7 | 79.9 | 102.6 | 237.2 | 227.5 | 61.1 | 57.1 | 54.8 | - | - | - |
Operating Cycle |
212.3 | 252.9 | 303.9 | 299.9 | 216.9 | 236.6 | 266.0 | 253.7 | 242.2 | 139.7 | 158.2 | 143.0 | - | - | - |
Cash Conversion Cycle |
154.6 | 187.1 | 226.8 | 221.6 | 157.2 | 156.7 | 163.4 | 16.5 | 14.7 | 78.7 | 101.1 | 88.2 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Avanos Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.03 | -1.66 | 0.14 | - | 0.09 | 0.04 | -0.02 | - | -0.08 | -1.46 | -0.01 | - | 0.34 | 0.27 | 0.11 | - | -0.73 | 0.8 | -0.17 | - | 0.4 | -0.06 | 0.08 | - | -0.24 | -0.17 | -0.43 | - | 0.09 | 0.75 | 0.43 | - | 0.35 | 0.37 | 0.27 | - | 0.19 | 0.14 | 0.3 | - | -10.1 | 0.17 | 0.47 | - | -0.16 | -0.1 | 0.89 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.11 | -1.51 | 0.43 | - | 0.38 | 0.25 | 0.33 | - | 0.13 | 0.05 | 0.13 | - | 0.37 | 0.31 | 0.42 | - | 0.67 | 0.25 | -0.06 | - | 0.67 | 0.41 | 0.23 | - | 0.16 | 0.15 | -0.34 | - | 0.67 | 0.52 | 0.02 | - | 0.81 | 0.43 | -0.03 | - | 1.48 | 1.06 | 1.05 | - | -8.85 | 1.17 | 1.23 | - | 1.61 | 0.65 | 1.7 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-8.94 | -8.41 | 1.63 | 0.42 | 0.12 | -0.53 | -6.19 | -5.86 | -4.61 | -3.07 | 3.44 | 2.66 | -0.12 | -4.15 | -2.19 | -0.50 | 1.04 | 5.36 | 2.17 | 1.59 | 0.68 | -1.76 | -2.16 | -3.15 | -2.82 | -1.59 | 1.76 | 4.60 | 5.97 | 7.01 | 5.70 | 3.83 | 4.65 | 4.11 | 3.29 | 2.70 | -41.88 | -87.29 | -87.12 | -41.77 | -42.27 | 1.82 | 0.76 | 1.98 | 4.28 | 7.08 | 7.38 | 2.30 | 2.30 | - | - | - | - | - | - | - | - | - | - |
ROA % |
-6.67 | -6.28 | 1.22 | 0.31 | 0.10 | -0.37 | -4.57 | -4.33 | -3.44 | -2.35 | 2.45 | 1.90 | -0.31 | -3.40 | -1.83 | -0.43 | 0.72 | 4.09 | 1.62 | 1.20 | 0.56 | -1.24 | -1.50 | -2.21 | -1.98 | -1.11 | 1.26 | 3.26 | 4.01 | 4.54 | 3.39 | 2.12 | 2.56 | 2.24 | 1.78 | 1.44 | -22.08 | -46.05 | -45.96 | -22.04 | -22.33 | 0.90 | 0.32 | 1.17 | 3.10 | 5.32 | 5.49 | 1.93 | 1.93 | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | - | - | - | - | - | - | - | 1.01 | 2.03 | 2.83 | 2.50 | 2.76 | 2.02 | 0.66 | -1.28 | -1.29 | -1.56 | -1.15 | -0.10 | -1.53 | -2.96 | -3.59 | -4.15 | -3.61 | -1.64 | -0.19 | 0.68 | -0.18 | -1.57 | -3.25 | -3.30 | -1.55 | 1.05 | 3.52 | 6.09 | -35.54 | -78.92 | -78.39 | -35.94 | -35.09 | 7.39 | 5.10 | 4.57 | 7.95 | 10.48 | 10.77 | 3.38 | 3.38 | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.7 | 4.0 | 4.1 | 3.5 | 3.9 | 3.8 | 3.8 | 3.7 | 3.4 | 3.9 | 4.0 | 3.6 | 3.5 | 3.5 | 3.5 | 4.8 | 4.8 | 4.3 | 4.2 | 4.0 | 4.0 | 4.0 | 4.0 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 3.4 | 2.2 | 2.2 | 2.2 | 2.2 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.5 | 2.4 | 2.4 | 2.4 | 6.1 | 6.1 | - | - | - | - | - | - | - | - | - | - |
DSO |
56.9 | 56.0 | 64.7 | - | 68.2 | 67.6 | 75.3 | - | 79.2 | 79.5 | 89.0 | - | 77.2 | 82.0 | 67.7 | - | 55.6 | 51.9 | 54.0 | - | 53.4 | 60.5 | 66.0 | - | 85.6 | 86.8 | 87.3 | - | 83.2 | 85.3 | 103.1 | - | 46.1 | 46.4 | 122.6 | - | 43.6 | 43.4 | 49.2 | - | 52.6 | 52.7 | 53.1 | - | 52.2 | 51.6 | 48.6 | - | 22.1 | - | - | - | - | - | - | - | - | - | - |
DIO |
145.8 | 154.5 | 162.6 | - | 191.8 | 197.6 | 210.4 | - | 183.5 | 221.9 | 223.3 | - | 229.4 | 215.0 | 159.2 | - | 154.6 | 148.2 | 168.6 | - | 171.4 | 199.6 | 183.4 | - | 174.3 | 181.1 | 186.5 | - | 183.4 | 167.3 | 148.5 | - | 119.6 | 128.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
51.2 | 52.2 | 58.9 | - | 62.2 | 65.0 | 72.5 | - | 70.7 | 79.7 | 85.7 | - | 80.3 | 84.3 | 60.4 | - | 58.5 | 56.9 | 64.0 | - | 68.6 | 79.9 | 87.8 | - | 99.1 | 103.0 | 176.4 | - | 256.7 | 234.2 | 238.3 | - | 224.8 | 241.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
202.7 | 210.6 | 227.3 | - | 260.1 | 265.1 | 285.7 | - | 262.8 | 301.4 | 312.2 | - | 306.7 | 297.0 | 226.9 | - | 210.1 | 200.1 | 222.6 | - | 224.8 | 260.2 | 249.4 | - | 259.8 | 267.9 | 273.8 | - | 266.6 | 252.7 | 251.6 | - | 165.8 | 175.1 | 122.6 | - | 43.6 | 43.4 | 49.2 | - | 52.6 | 52.7 | 53.1 | - | 52.2 | 51.6 | 48.6 | - | 22.1 | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
151.5 | 158.4 | 168.4 | - | 197.9 | 200.1 | 213.2 | - | 192.0 | 221.7 | 226.6 | - | 226.4 | 212.7 | 166.5 | - | 151.6 | 143.2 | 158.6 | - | 156.2 | 180.3 | 161.7 | - | 160.7 | 164.9 | 97.4 | - | 9.9 | 18.5 | 13.3 | - | -59.0 | -66.8 | 122.6 | - | 43.6 | 43.4 | 49.2 | - | 52.6 | 52.7 | 53.1 | - | 52.2 | 51.6 | 48.6 | - | 22.1 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Avanos Medical, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
$ 11.94 | -1.73 % | $ 1.79 B |  USA |
 |
Butterfly Network
BFLY
|
$ 4.3 | 2.51 % | $ 910 M | USA |
 |
Bruker Corporation
BRKR
|
$ 36.29 | 4.1 % | $ 5.41 K | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.34 | -1.79 % | $ 264 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | USA |
 |
Delcath Systems
DCTH
|
$ 8.95 | -1.65 % | $ 321 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M |  China |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
FONAR Corporation
FONR
|
$ 18.35 | 0.05 % | $ 120 M | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
Inogen
INGN
|
$ 6.26 | -2.92 % | $ 167 M | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 84.81 | -0.61 % | $ 2.95 B | USA |
 |
LivaNova PLC
LIVN
|
$ 63.31 | 0.11 % | $ 3.45 B |  Britain |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
$ 5.87 | -3.29 % | $ 67.6 M | USA |
 |
Medtronic PLC
MDT
|
$ 86.97 | -0.23 % | $ 112 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
$ 1.35 | -0.37 % | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Orthofix Medical
OFIX
|
$ 11.88 | 0.08 % | $ 470 M |  Curacao |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | USA |
 |
AxoGen
AXGN
|
$ 32.34 | 1.86 % | $ 1.49 B | USA |
 |
Penumbra
PEN
|
$ 335.16 | -0.12 % | $ 13 B | USA |
 |
CONMED Corporation
CNMD
|
$ 36.38 | -0.68 % | $ 1.13 B | USA |
 |
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | USA |
 |
Insulet Corporation
PODD
|
$ 224.56 | -1.11 % | $ 15.8 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B |  Israel |
 |
Profound Medical Corp.
PROF
|
$ 5.22 | -3.33 % | $ 180 M |  Canada |
 |
Electromed
ELMD
|
$ 24.4 | -0.37 % | $ 206 M | USA |
 |
Misonix, Inc.
MSON
|
- | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.75 | -4.82 % | $ 160 M | USA |
 |
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 0.68 | 0.95 % | $ 37 M | USA |
 |
Aethlon Medical
AEMD
|
$ 2.24 | -2.61 % | $ 3.5 M | USA |
 |
Sintx Technologies
SINT
|
$ 2.58 | 1.18 % | $ 7.16 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 10.96 | 5.68 % | $ 1.48 B | USA |
 |
Stryker Corporation
SYK
|
$ 329.09 | -1.05 % | $ 126 B | USA |
 |
Myomo
MYO
|
$ 0.72 | 2.1 % | $ 30.1 M | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.28 | -0.87 % | $ 601 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 100.0 | 0.81 % | $ 1.27 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 2.38 | -2.25 % | $ 140 M | Israel |